AGMBAgomAb Therapeutics NV American Depositary Shares

ADRCNasdaq (XNAS)·USD

Identity

Security key: 11419
Ticker: AGMB
Type: ADRC — American Depository Receipt Common
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2026-02-06
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: AGMB

Detail

Enriched 2026-08-14 20:47

Market cap: $694,888,927.25
Shares outstanding (class): 49,247,975
Shares outstanding (weighted): 49,247,975
SIC: —
Employees: 62
Location: —
Homepage: https://www.agomab.com
Description: AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

Market cap and share counts drift.

Funds holding this security

1 funds · 4 positions · $7.64M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
abrdn Healthcare Investors —	—	$3.05M	0.27%	290,869 NS	FIGI
abrdn World Healthcare Fund —	—	$2.88M	0.60%	275,000 NS	FIGI
abrdn Life Sciences Investors —	—	$1.49M	0.27%	141,787 NS	FIGI
Federated Hermes Kaufmann Fund II Federated Hermes Insurance Series	—	$221.4K	0.23%	21,108 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERAGMB
FIGI_COMPOSITEBBG01ZPFZLR6
FIGI_SHARE_CLASSBBG01ZPFZNN6
CIK0002020932
ISINUS00860C1027
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: AgomAb Therapeutics is a biopharmaceutical company developing antibody therapeutics, so it falls under healthcare biotechnology.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.